These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 7529341)

  • 1. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.
    Gann PH; Hennekens CH; Stampfer MJ
    JAMA; 1995 Jan; 273(4):289-94. PubMed ID: 7529341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
    JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
    Gann PH; Ma J; Catalona WJ; Stampfer MJ
    J Urol; 2002 Jun; 167(6):2427-34. PubMed ID: 11992051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.
    Eastham JA; Riedel E; Scardino PT; Shike M; Fleisher M; Schatzkin A; Lanza E; Latkany L; Begg CB;
    JAMA; 2003 May; 289(20):2695-700. PubMed ID: 12771116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial.
    Auvinen A; Määttänen L; Finne P; Stenman UH; Aro J; Juusela H; Rannikko S; Tammela TL; Hakama M
    Int J Cancer; 2004 Oct; 111(6):940-3. PubMed ID: 15300807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
    Aus G; Damber JE; Khatami A; Lilja H; Stranne J; Hugosson J
    Arch Intern Med; 2005 Sep; 165(16):1857-61. PubMed ID: 16157829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
    Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
    Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.